Axa’s NuVasive, Inc. NUVA Stock Holding History

Axa’s Portfolio NUVA Stock Details NUVA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q2	–	Sell	-20,440	Closed	-$844K	–	1192
2023 Q1	$844K	Sell	20,440 -15,500	-43%	-$663K	﹤0.01%	895
2022 Q4	$1.48M	Buy	35,940 +800	+2%	+$32.4K	0.01%	822
2022 Q3	$1.54M	Buy	35,140 +13,800	+65%	+$669K	0.01%	797
2022 Q2	$1.05M	Buy	21,340 +900	+4%	+$48.3K	﹤0.01%	874
2022 Q1	$1.16M	Sell	20,440 -339,881	-94%	-$18.1M	﹤0.01%	928
2021 Q4	$18.9M	Buy	360,321 +16,883	+5%	+$918K	0.05%	374
2021 Q3	$20.6M	Buy	343,438 +7,765	+2%	+$479K	0.06%	329
2021 Q2	$22.8M	Sell	335,673 -34,095	-9%	-$2.33M	0.06%	317
2021 Q1	$24.2M	Sell	369,768 -452,428	-55%	-$27.1M	0.07%	307
2020 Q4	$46.3M	Sell	822,196 -314,314	-28%	-$15.5M	0.15%	165
2020 Q3	$55.2M	Sell	1,136,510 -28,990	-2%	-$1.56M	0.2%	120
2020 Q2	$64.9M	Buy	1,165,500 +108,064	+10%	+$6.25M	0.26%	98
2020 Q1	$53.6M	Buy	1,057,436 +65,674	+7%	+$4.4M	0.27%	94
2019 Q4	$76.7M	Buy	991,762 +284,735	+40%	+$20.1M	0.31%	80
2019 Q3	$44.8M	Sell	707,027 -26,435	-4%	-$1.65M	0.18%	150
2019 Q2	$42.9M	Sell	733,462 -122,293	-14%	-$7.22M	0.17%	166
2019 Q1	$48.6M	Sell	855,755 -35,750	-4%	-$1.9M	0.19%	154
2018 Q4	$44.2M	Sell	891,505 -22,843	-2%	-$1.37M	0.19%	137
2018 Q3	$64.9M	Sell	914,348 -40,240	-4%	-$2.56M	0.24%	116
2018 Q2	$49.8M	Buy	954,588 +9,370	+1%	+$491K	0.19%	145
2018 Q1	$49.4M	Buy	945,218 +144,743	+18%	+$7.34M	0.2%	139
2017 Q4	$46.8M	Buy	800,475 +355,908	+80%	+$20.2M	0.18%	161
2017 Q3	$24.7M	Buy	444,567 +66,754	+18%	+$4.42M	0.11%	238
2017 Q2	$29.1M	Buy	377,813 +64,796	+21%	+$4.84M	0.13%	209
2017 Q1	$23.4M	Buy	313,017 +69,098	+28%	+$5.01M	0.11%	243
2016 Q4	$16.4M	Sell	243,919 -57	-0%	-$3.67K	0.08%	293
2016 Q3	$16.3M	Buy	243,976 +67,808	+38%	+$4.32M	0.07%	292
2016 Q2	$10.5M	Buy	176,168 +2,443	+1%	+$132K	0.05%	383
2016 Q1	$8.45M	Buy	173,725 +7,590	+5%	+$344K	0.04%	431
2015 Q4	$8.99M	Buy	166,135 +3,416	+2%	+$174K	0.04%	412
2015 Q3	$7.85M	Buy	162,719 +4,353	+3%	+$225K	0.03%	442
2015 Q2	$7.5M	Buy	158,366 +1,700	+1%	+$79.5K	0.03%	477
2015 Q1	$7.21M	Buy	156,666 +797	+0.5%	+$37K	0.03%	480
2014 Q4	$7.35M	Buy	155,869 +501	+0.3%	+$20.9K	0.03%	463
2014 Q3	$5.42M	Buy	155,368 +5,379	+4%	+$191K	0.02%	515
2014 Q2	$5.33M	Sell	149,989 -6,282	-4%	-$215K	0.02%	525
2014 Q1	$6M	Buy	156,271 +5,074	+3%	+$186K	0.03%	487
2013 Q4	$4.89M	Buy	151,197 +3,704	+3%	+$111K	0.02%	526
2013 Q3	$3.61M	Buy	147,493 +537	+0.4%	+$13.2K	0.02%	599
2013 Q2	$3.64M	Buy	+146,956	New	+$3.22M	0.02%	547

Other funds holding NUVA

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Magnetar Financial Evanston, Illinois $9.84B AUM 190.64% 1-Year Est. Return

Kryger Capital London, United Kingdom $1.41B AUM 86.31% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Macquarie Group Sydney, NSW 2000, Australia $16.8B AUM 27.39% 1-Year Est. Return

AAM

Alpine Associates Management Palm Beach, Florida $1.7B AUM 97.55% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

PIM

Paradice Investment Management Denver, Colorado $532M AUM 29.6% 1-Year Est. Return

WCMNY

Westchester Capital Management (New York) Valhalla, New York $2.21B AUM 26.02% 1-Year Est. Return

Axa's NUVA Position: Q2 2023 in Review

Axa sold out of NuVasive, Inc. (NUVA) in Q2 2023, closing a stake of 20,440 shares — an estimated $844K sold.

Axa first reported a position in NUVA in Q2 2013 and held it in 40 quarters. The position peaked at $76.7M in Q4 2019. 228 funds tracked by Wall St. Rank hold NUVA as of Q2 2023.

Axa reported no remaining NuVasive, Inc. position as of Q2 2023 after selling out during the quarter.
Axa sold 20,440 NuVasive, Inc. shares in Q2 2023, an estimated $844K.
Axa first reported a position in NuVasive, Inc. in Q2 2013 and held it in 40 quarters.
Axa's NuVasive, Inc. position peaked at $76.7M in Q4 2019.
228 funds tracked by Wall St. Rank held NuVasive, Inc. as of Q2 2023.

Based on Axa's 13F filing for Q2 2023, filed 14 Aug 2023.